Results 101 to 110 of about 28,303 (260)
Diabetes, Obesity and Metabolism, EarlyView.ABSTRACT Objective To examine the effect of second‐line treatments (insulin secretagogues, thiazolidinediones, glucagon‐like peptide‐1 (GLP‐1) receptor agonists, dipeptidyl peptidase‐4 (DPP‐4) inhibitors or sodium‐glucose co‐transporter 2 (SGLT‐2) inhibitors) on time to insulin initiation among patients with type 2 diabetes.
Ya‐Hui Yu +6 more
wiley +1 more source
Diabetes, Obesity and Metabolism, EarlyView.ABSTRACT Aims The study aims (1) to evaluate the quality of diabetes care considering guideline‐recommended medical therapies, cardiometabolic factors, and self‐management of health behaviours among older adults with diabetes in Germany, and (2) to examine time trends.
Yong Du +6 more
wiley +1 more source
Dipeptidyl peptidase-4 inhibitors and osteoporosis
Journal of the Chinese Medical Association, 2022 Lee, Wen-Ling +2 more
openaire +2 more sources
Diabetes, Obesity and Metabolism, EarlyView.ABSTRACT Aims The association between glucagon‐like peptide‐1 receptor agonist (GLP‐1RA) use and the development of bowel obstruction/ileus remains unclear, and evidence for specific bowel obstruction/ileus subtypes remains limited. We examined the association between GLP‐1RA use and the incidence of bowel obstruction/ileus subtypes across different ...
Yuichiro Matsuo +3 more
wiley +1 more source
Health economic evaluation of dipeptidyl peptidase-4 inhibitors
Indian Journal of Endocrinology and Metabolism, 2011 Vishvas Garg
doaj +1 more source
Diabetes, Obesity and Metabolism, EarlyView.ABSTRACT Aims Sodium–glucose cotransporter 2 inhibitors (SGLT2i) are commonly withheld during hospitalisation because of concerns about diabetic ketoacidosis. We examined whether hospitalisation was associated with discontinuation of SGLT2i and compared patterns with another anti‐hyperglycaemic medicine without similar inpatient safety concerns ...
Tamara Y. Milder +13 more
wiley +1 more source
Diabetes, Obesity and Metabolism, EarlyView.ABSTRACT Aims To identify low‐ and high‐risk intervals for major adverse cardiovascular events (MACE) and all‐cause mortality according to lipid ratios in adults with Type 2 diabetes mellitus (T2DM), stratified by sex. Materials and Methods We used primary care electronic health records from the Spanish National Health Service including 303 199 adults ...
Enrique Carretero‐Anibarro +5 more
wiley +1 more source
SGLT‐2 Inhibitors are Associated With a Lower Risk of Multiple Myeloma
European Journal of Haematology, EarlyView.ABSTRACT Aims We aimed to investigate drug response of sodium‐glucose transport protein‐2 inhibitors (SGLT2i) in multiple myeloma (MM), as SGLT2i have potential favorable effects on conditions related to MM. Methods We conducted a pharmacoepidemiologic study with a US nationwide health insurance claim data using Cox models to investigate the ...
Enze Liu +6 more
wiley +1 more source
The Role of Neuropeptide Y in Dental Pulp: Balancing Neurogenic Inflammation and Pain Modulation
International Endodontic Journal, EarlyView.ABSTRACT Background Dental pulp is a densely innervated, low‐compliance tissue in which neurogenic inflammation can rapidly escalate into oedema, raised intrapulpal pressure, microvascular compromise, and pain. While Substance P (SP) and Calcitonin gene‐related peptide (CGRP) are well‐established drivers of pulp vasodilation, the Neuroopeptide Y (NPY ...
Javier Caviedes‐Bucheli +3 more
wiley +1 more source